

Short Survey #3: Questions for physicians to evaluate the physician didactic sessions

1. For its applicability to your practice, what has been the most important and relevant message for you?

2. Which of the key messages did you find the most discomfort with (if any), and why?

3. What is the most noteworthy aspect of your practice that you would change after having attended this session?

4. What could the presenter have done to improve the effectiveness or impact of the session?

Long Survey #3: Questions for physicians to evaluate the physician didactic sessions

1. Please rate your comfort level with the learning objectives summarized in the three key messages; and if you have any comments on the key message, please feel free to add them in the space provided.

All PPIs are equally efficacious as initial therapy (the major difference is cost).

very comfortable	1	2	3	4	5	very uncomfortable
------------------	---	---	---	---	---	--------------------

Comments?

More may not always be better (double-dose PPIs may not be necessary).

very comfortable	1	2	3	4	5	very uncomfortable
------------------	---	---	---	---	---	--------------------

Comments?

PPIs are not efficacious in the treatment of asthma, chronic cough, and laryngeal symptoms that may be associated with GERD.

very comfortable	1	2	3	4	5	very uncomfortable
------------------	---	---	---	---	---	--------------------

Comments?

2. On average, how often do you see patients who are on PPIs (this could include patients who were prescribed a PPI by you or someone else)? (Select one.)

- Frequently (at least once a day)
- Sometimes (up to several times a week)
- Rarely (up to several times a month)
- Extremely rarely (I see this only a few times a year)
- Never

3. For those patients that are on PPIs, over what time period do the majority of your patients take a PPI? (Select one.)

- Very short term, such as for only one script (30 days)
- Short term, such as from one to four months
- Medium term, such as more than four months but less than a year
- Long term, such as for more than a year
- Very long term, such as for several years or more
- I don't know (can't even guess)

4. How often are those patients in your practice taking PPIs reassessed to determine the appropriateness of their dose or their continued need for the PPI? (Select one.)

- Always (every visit)
- Sometimes (every few months)
- Rarely (at least once per year)
- Extremely rarely or never (almost never)
- I don't know (can't even guess)

5. Would you be comfortable speaking to patients about the key issues raised in the session? (Select one.)

very comfortable	1	2	3	4	5	very uncomfortable
------------------	---	---	---	---	---	--------------------

Please briefly comment on your comfort level:

6. (a) How important is it that you advise patients of the comparative costs of the various PPIs?

very important	1	2	3	4	5	not important at all
----------------	---	---	---	---	---	----------------------

(b) How important is it that you to recommend lower-cost agents (such as H2 antagonists or antacids)?

very important	1	2	3	4	5	not important at all
----------------	---	---	---	---	---	----------------------

(c) Can you briefly comment on the level of importance you indicated in parts (a) and (b) of this question?

7. How likely would you consider reassessing and/or changing the patient's medication to lower cost agents? (Check one.)

- Very likely
- Somewhat likely
- Neutral
- Somewhat unlikely
- Very unlikely

8. If you checked "somewhat" or "very likely" to the above question, when do you think you would take these actions? (check the most appropriate)

- Right away
- Within two months
- Within six months
- Within a year

9. Do you have any suggestions on how we could improve this presentation?
Please be as specific as possible.

10. Please describe any significant obstacles to your applying each of the following key messages in your practice.

All PPIs are equally efficacious as initial therapy (the major difference is cost).

More may not always be better (double-dose PPIs may not be necessary).

PPIs are not efficacious in the treatment of asthma, chronic cough, and laryngeal symptoms that may be associated with GERD.

